Gene therapy biotech Locanabio to shutter by year’s end
Gene therapy biotech Locanabio will shut down by the end of this year, the startup’s CEO posted on LinkedIn Wednesday afternoon.
“While we continue to believe in the potential of our RNA-targeted gene therapy platform to deliver transformative therapies, the decision was made due to the time and capital required to deliver clinical data in the current challenging funding environment,” CEO Jim Burns wrote in the post. Burns joined the company in 2019 after leading Casebia Therapeutics and, before that, heading up R&D at Sanofi.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.